Global Array Market (Life Science and Biotechnology Instruments): Key Developments
In November 2022, Sengenics, a precision medicine company, announced the commercial launch of Dual-Color IgG/IgA Assay Services. The new Dual-Color Assays accelerate the pace and expand the biological space in the quest to discover new autoantibody biomarkers.
In October 2020, researchers emphasized in an article published in the Journal of Proteins & Proteomics that advances in proteome technology will not only expedite efforts in combating the coronavirus pandemic but will also help to address the current COVID-19 situation.
In February 2020, the U.S. Food & Drug Administration changed the definition of a biologic to include in synthetic peptides and chemically synthesized polypeptides with a sequence of at least 40 amino acids but no more than 100 amino acids (synthetic proteins).
In April 2021, the National Center for Biotechnology information announced the introduction of CovidArray, a microarray-based test to detect COVID-19 markers N1 and N2 in nasopharyngeal swab samples. The universal microarray can detect the genotypes of six mutated bases related to COVID-19.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients